<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198961</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-54148</org_study_id>
    <nct_id>NCT04198961</nct_id>
  </id_info>
  <brief_title>Electronic Intervention to Chronic Opioid Therapy</brief_title>
  <official_title>An Electronic Chart Intervention to Improve Safety for Patients on Chronic Opioid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will attempt to apply an electronic chart intervention to improve safety for&#xD;
      patients on chronic opioid medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2020</start_date>
  <completion_date type="Actual">June 17, 2021</completion_date>
  <primary_completion_date type="Actual">June 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of patients who receives naloxone prescription</measure>
    <time_frame>baseline, 1, 3- and 6-months and 12 months</time_frame>
    <description>Change in the number of patients who receives naloxone prescription</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of number of documentation about safety discussions</measure>
    <time_frame>baseline, 1, 3- and 6-months and 12 months</time_frame>
    <description>change of number of documentation about safety discussions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of number of order for urine toxicology screening</measure>
    <time_frame>baseline, 1, 3- and 6-months and 12 months</time_frame>
    <description>change of number of order for urine toxicology screening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of number of documentation of prescription drug monitoring program (CURES) results</measure>
    <time_frame>baseline, 1, 3- and 6-months and 12 months</time_frame>
    <description>change of number of documentation of prescription drug monitoring program (CURES) results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of number of signed opioid informed consent forms</measure>
    <time_frame>baseline, 1, 3- and 6-months and 12 months</time_frame>
    <description>change of number of signed opioid informed consent forms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of patients on long-term high risk doses of opioid pain medications</measure>
    <time_frame>baseline, 1, 3- and 6-months and 12 months</time_frame>
    <description>decreases in daily dose of opioids and number of patients on opioids â‰¥ 90mg MEDD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Chronic Opioid Therapy</condition>
  <arm_group>
    <arm_group_label>Electronic Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized opioid taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>opioid prescribing</intervention_name>
    <description>Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.</description>
    <arm_group_label>Electronic Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients prescribed long-term opioid therapy of doses greater than 90 morphine&#xD;
             equivalent daily dose (MEDD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients prescribed short-term opioid medications for acute pain (less than a 90-day&#xD;
             supply over the past 120 days), sublingual buprenorphine, methadone maintenance for&#xD;
             opioid use disorder or with oncology or palliative care diagnoses will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiqiong Deng, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Huiqiong Deng</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

